3 Big Pharma Outperformers to Watch Out For in the Near Term
The recently ended third-quarter earnings season was a good one for the drug and biotech sector with many companies beating estimates on both counts. Some companies also raised their expectations for both earnings and sales, ... [Read]
Pfizer And BioNTech to Provide U.S. Government an Additional 50 Million Pediatric Doses of COVID-19 Vaccine to Support Further Preparedness for Future Needs
Doses expected to be delivered by April 2022 NEW YORK and MAINZ, GERMANY, October 28, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government has purchased 50 ... [Read]
Vertex’s (VRTX) Early Type I Diabetes Study Data Promising
Vertex Pharmaceuticals Incorporated VRTX announced data on the first patient from an ongoing phase I/II study evaluating its investigational cell-based therapy, VX-880 for the treatment of type I diabetes (T1D) with impaired hypoglycemic awareness and ... [Read]
Bristol Myers (BMY) Gets Positive CHMP Opinion for Zeposia in UC
Bristol-Myers Squibb Company BMY announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion on, and recommended the approval of its sphingosine-1-phosphate (S1P) receptor modulator Zeposia ... [Read]
Psychedelic and Cannabis Stocks Could Win if US Ends the War on Drugs
The first-ever bill to decriminalize all drugs in the US was introduced to Congress on June 15, 2021. Democrat US Reps. Cori Bush (Missouri’s 1st congressional district rep) and Bonnie Watson Coleman (New Jersey’s 12th ... [Read]
FDA Approves Biogen’s (NASDAQ:BIIB) New Alzheimer Drug
Biogen (NASDAQ:BIIB) and Eisai Co., Ltd (TYO:4523) has just had their Alzheimer’s disease drug Aduhelm approved by the FDA on June 7, 2021. Investors holding the stock on Friday June 4 had their shares close ... [Read]
Halozyme Therapeutics (HALO) Down 19.3% Since Last Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for Halozyme Therapeutics (HALO). Shares have lost about 19.3% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading ... [Read]
ALXN vs. BMRN: Which Stock Is the Better Value Option?
Investors interested in Medical – Biomedical and Genetics stocks are likely familiar with Alexion Pharmaceuticals (ALXN) and BioMarin Pharmaceutical (BMRN). But which of these two stocks presents investors with the better value opportunity right now? ... [Read]
Bristol Myers’ (BMY) Opdivo Label Expansion Gets Priority Review
Bristol Myers Squibb BMY announced that the FDA has accepted its supplemental biologics license application (sBLA), seeking approval for a further label expansion of immuno-oncology drug, Opdivo (nivolumab). The company is seeking approval of the ... [Read]
Cocrystal Pharma (COCP) Completes Research Obligations With Merck
Cocrystal Pharma, Inc. COCP announced that it has completed all research obligations under the Merck MRK exclusive worldwide license and collaboration agreement and the latter is now solely responsible for further development of the influenza ... [Read]